<DOC>
	<DOC>NCT02038764</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple doses of PF-06342674. Several dose levels will be evaluated.</brief_summary>
	<brief_title>A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>Women and men age 18 and older. Diagnosis of type 1 diabetes within 2 years of randomization. Peak stimulated Cpeptide levels â‰¥ 0.15 ng/mL. Anticipated ongoing use of diabetes medications other than insulin. Evidence or history of diabetic complications with significant endorgan damage. Episode of severe hypoglycemia within 60 days of randomization. Multiple hospitalizations for diabetic ketoacidosis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>RN168</keyword>
	<keyword>Adults</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>T1D</keyword>
</DOC>